T. Rowe Price Associates’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-128,228
| Closed | -$188K | – | 3092 |
|
|
2022
Q2 | $188K | Sell |
128,228
-12,869
| -9% | -$9.46K | ﹤0.01% | 2622 |
|
|
2022
Q1 | $162K | Buy |
141,097
+83,839
| +146% | +$137K | ﹤0.01% | 2758 |
|
|
2021
Q4 | $143K | Sell |
57,258
-36,900
| -39% | -$145K | ﹤0.01% | 2820 |
|
|
2021
Q3 | $482K | Sell |
94,158
-160,208
| -63% | -$973K | ﹤0.01% | 2400 |
|
|
2021
Q2 | $2.11M | Sell |
254,366
-685,865
| -73% | -$5.78M | ﹤0.01% | 1716 |
|
|
2021
Q1 | $8.19M | Sell |
940,231
-602,356
| -39% | -$6.23M | ﹤0.01% | 1420 |
|
|
2020
Q4 | $16.8M | Sell |
1,542,587
-42,465
| -3% | -$524K | ﹤0.01% | 1260 |
|
|
2020
Q3 | $18.9M | Sell |
1,585,052
-442,195
| -22% | -$5.92M | ﹤0.01% | 1170 |
|
|
2020
Q2 | $32.6M | Buy |
2,027,247
+645,097
| +47% | +$11.3M | ﹤0.01% | 988 |
|
|
2020
Q1 | $21.4M | Sell |
1,382,150
-20,943
| -1% | -$450K | ﹤0.01% | 1049 |
|
|
2019
Q4 | $34.5M | Buy |
1,403,093
+1,372,023
| +4,416% | +$20.4M | ﹤0.01% | 1028 |
|
|
2019
Q3 | $320K | Sell |
31,070
-604,593
| -95% | -$7.63M | ﹤0.01% | 2259 |
|
|
2019
Q2 | $7.98M | Buy |
635,663
+231,109
| +57% | +$2.97M | ﹤0.01% | 1350 |
|
|
2019
Q1 | $5.01M | Buy |
+404,554
| New | +$4.52M | ﹤0.01% | 1398 |
|
|
2018
Q1 | – | Sell |
-359,512
| Closed | -$4.51M | – | 2600 |
|
|
2017
Q4 | $4.51M | Buy |
359,512
+344,800
| +2,344% | +$5.01M | ﹤0.01% | 1445 |
|
|
2017
Q3 | $280K | Hold |
14,712
| – | – | ﹤0.01% | 2303 |
|
|
2017
Q2 | $222K | Sell |
14,712
-1,100
| -7% | -$16.6K | ﹤0.01% | 2340 |
|
|
2017
Q1 | $271K | Buy |
15,812
+12
| +0.1% | +$160 | ﹤0.01% | 2298 |
|
|
2016
Q4 | $191K | Sell |
15,800
-11,100
| -41% | -$116K | ﹤0.01% | 2393 |
|
|
2016
Q3 | $265K | Buy |
26,900
+7,500
| +39% | +$68.5K | ﹤0.01% | 2263 |
|
|
2016
Q2 | $199K | Buy |
19,400
+7,000
| +56% | +$78.1K | ﹤0.01% | 2333 |
|
|
2016
Q1 | $150K | Hold |
12,400
| – | – | ﹤0.01% | 2350 |
|
|
2015
Q4 | $199K | Buy |
+12,400
| New | +$184K | ﹤0.01% | 2304 |
|
|
2014
Q4 | – | Sell |
-585,771
| Closed | -$15.9M | – | 2572 |
|
|
2014
Q3 | $15.9M | Buy |
585,771
+61,240
| +12% | +$1.9M | ﹤0.01% | 1179 |
|
|
2014
Q2 | $16.3M | Buy |
+524,531
| New | +$12.4M | ﹤0.01% | 1171 |
|
Other funds holding EPZM
T. Rowe Price Associates's EPZM Position: Q3 2022 in Review
T. Rowe Price Associates sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 128,228 shares — an estimated $188K sold.
T. Rowe Price Associates first reported a position in EPZM in Q2 2014 and held it in 25 quarters. The position peaked at $34.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- T. Rowe Price Associates reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- T. Rowe Price Associates sold 128,228 Epizyme, Inc shares in Q3 2022, an estimated $188K.
- T. Rowe Price Associates first reported a position in Epizyme, Inc in Q2 2014 and held it in 25 quarters.
- T. Rowe Price Associates's Epizyme, Inc position peaked at $34.5M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.